The Brain's Cannabis System Changes With Age — And May Hold Keys to Fighting Neurodegeneration

Normal aging shows CB1 receptor downregulation and increased endocannabinoid-degrading enzymes, contributing to cognitive and motor decline. In neurodegenerative diseases, these changes become extreme. However, elevated endocannabinoid levels (from reduced FAAH/MAGL) and CB2 receptor upregulation may represent protective compensatory responses. Pharmacological targeting of specific ECS components shows neuroprotective potential.

Comprehensive narrative review synthesizing 30-40 years of research on the endocannabinoid system across the lifespan, from neurodevelopment through senescence. Covers normal aging changes and their extreme presentation in neurodegenerative disorders, with discussion of therapeutic implications.

As global lifespans increase, neurodegenerative diseases are expanding. Understanding how the brain's endocannabinoid system changes with age could lead to interventions that slow cognitive decline and protect against diseases like Alzheimer's and Parkinson's.

The dual nature of ECS changes in aging is fascinating: some changes contribute to decline while others protect against it. This suggests that nuanced pharmacological approaches — boosting protective components while addressing harmful ones — could be more effective than blanket cannabinoid therapy.

Narrative review spans decades of research with varying methodologies. Animal models may not perfectly reflect human aging. Translation from basic science to clinical therapy remains challenging. Individual variation in aging and ECS function is large.